GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Cash And Cash Equivalents

OpGen (LTS:0A8L) Cash And Cash Equivalents : $0.29 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is OpGen Cash And Cash Equivalents?

OpGen's quarterly cash and cash equivalents declined from Mar. 2023 ($7.04 Mil) to Jun. 2023 ($3.24 Mil) but then stayed the same from Jun. 2023 ($3.24 Mil) to Sep. 2023 ($0.29 Mil).

OpGen's annual cash and cash equivalents increased from Dec. 2020 ($13.36 Mil) to Dec. 2021 ($36.08 Mil) but then declined from Dec. 2021 ($36.08 Mil) to Dec. 2022 ($7.44 Mil).


OpGen Cash And Cash Equivalents Historical Data

The historical data trend for OpGen's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Cash And Cash Equivalents Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.57 2.71 13.36 36.08 7.44

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.28 7.44 7.04 3.24 0.29

OpGen Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


OpGen  (LTS:0A8L) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


OpGen Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of OpGen's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (LTS:0A8L) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines